Classification and treatments

Mast Cell Activation Disorders: Current Concepts and Clinical Framework

Mast cell activation disorders (MCAD) encompass a spectrum of clonal and non-clonal diseases in which **mast cells release mediators inappropriately or excessively, producing recurrent, multisystem symptoms that range from nuisance to life-threatening anaphylaxis**[1][2][3]. Despite their rarity, heightened recognition, improved biochemical testing, and recent therapeutic advances have transformed the field over the past decade[4][5]. This review synthesises contemporary evidence on epidemiology, biology, classification, diagnosis, and management, and concludes with a practical, organ-based list of signs and symptoms that clinicians can use to define MCAD in daily practice.

Epidemiology and Burden

The combined prevalence of systemic mastocytosis (SM) and mast cell activation syndrome (MCAS) in population-based registries remains low—approximately 28 per 100 000 for mastocytosis in northern Europe[6]—yet referral-centre studies reveal heavy diagnostic traffic driven by undifferentiated multisystem complaints[7][8]. Rigorous application of consensus criteria shows that **idiopathic MCAS is confirmed in only 2–5% of patients referred for suspected disease**, underscoring both under- and over-diagnosis[7][9]. Children present predominantly with cutaneous mastocytosis, whereas adults account for most clonal SM cases and nearly all MCAS referrals[10][11].

Mast Cell Biology and Mediators

Mast cells reside in vascularised connective tissues where they store **tryptase, histamine, heparin, prostaglandin D₂ (PGD₂), leukotrienes and cytokines** in cytoplasmic granules[12][13]. Activation—via IgE cross-linking, KIT mutation, complement, drugs, physical stimuli or idiopathic signals—results in degranulation followed by de-novo lipid mediator synthesis[14][15]. These mediators drive vasodilation, smooth-muscle spasm, nociceptor activation and tissue remodelling, explaining the protean clinical picture[16][12].

Classification of Mast Cell Activation Disorders

The 2022 WHO and 2022 International Consensus Classification (ICC) divide MCAD into three overarching groups[4][17]:

| Disease group | Hallmark features | Typical examples |

|---|---|---|

| **Primary (clonal)** | KIT mutation, aberrant CD25/CD30 expression, increased mast-cell burden | Indolent, smouldering or aggressive **systemic mastocytosis**; mast cell leukaemia; mast cell sarcoma |

| **Secondary (reactive)** | Physiological mast cells activated by external illness | IgE-dependent allergy, parasitosis, autoimmune disease |

| **Idiopathic MCAS** | Normal mast-cell number but episodic systemic mediator release with no clonal or reactive cause | “True” idiopathic MCAS after exclusion of above |

Bone-marrow mastocytosis is now recognised as a discrete indolent SM subtype[17]. Variant allele frequency ≥10% for **KIT D816V** has been incorporated as a “B-finding,” reflecting high mast-cell burden without organ damage[4].

Pathophysiology

In clonal disease, constitutively active **KIT D816V** drives uncontrolled proliferation and lowers the threshold for degranulation[18][17]. In secondary and idiopathic MCAS, diverse triggers converge on intracellular calcium flux and phospholipase pathways, culminating in release of histamine and **PGD₂**, the latter a potent bronchoconstrictor and vasodilator implicated in flushing, hypotension and neuro-sensory hyperreactivity[12][14][15]. Mast-cell mediators also recruit eosinophils and Th2 lymphocytes, perpetuating inflammation[11].

Clinical Manifestations

Multisystem Symptomatology

MCAD symptoms wax and wane, often involving several organs simultaneously[2][19][11]. **Skin**, **gastrointestinal**, **cardiovascular**, **respiratory** and **neuro-psychiatric** systems dominate presentations, but almost any tissue can be affected[20][21][11].

| Organ system | Representative signs and symptoms | Key mediators |

|---|---|---|

| **Skin** | Flushing, urticaria, pruritus, dermatographism, angio-oedema | Histamine, PGD₂[19][2] |

| **Cardiovascular** | Tachycardia, hypotension, hypertension, presyncope/syncope, palpitations | Histamine, heparin[2][3] |

| **Gastrointestinal** | Nausea, abdominal cramp, diarrhoea/constipation, reflux, bloating | Histamine, leukotrienes[19][11] |

| **Respiratory / Naso-ocular** | Wheeze, throat tightness, nasal congestion, conjunctival injection | Histamine, PGD₂[19][2] |

| **Neurological / Psychiatric** | Headache, cognitive “brain fog,” paresthesia, anxiety, depression | Cytokines, PGD₂[22][11] |

| **Musculoskeletal** | Bone pain, myalgia, osteopenia/osteoporosis | Heparin, cytokines[17][11] |

| **Genitourinary** | Dysuria, interstitial cystitis, menorrhagia | Histamine[21][11] |

| **Constitutional** | Fatigue, chills, low-grade fever | Cytokines[21][11] |

The largest prospective MCAS cohort (N = 413) illustrates the frequency of core symptoms[21].

*Horizontal bar chart depicting the ten most common symptoms in MCAS.*

Anaphylaxis

Severe episodes reflect systemic mediator surge and occur spontaneously or after triggers such as **Hymenoptera stings, alcohol, temperature change or drugs**[20][23]. The risk is highest in SM with elevated basal tryptase and hereditary α-tryptasemia[24][25].

Diagnostic Criteria

Consensus mandates three pillars[2][3]:

1. **Typical episodic symptoms involving ≥ 2 organ systems** (Table above)[2].
2. **Objective biochemical evidence of mast-cell activation**:

- Serum tryptase rise fulfilling the **“20% + 2-ng/mL” rule** over the individual baseline during an attack[26][24] or a ratio >1.685 to improve specificity in hereditary α-tryptasemia and SM[25].

- Alternatively, elevation of other mast-cell mediators—urinary **11β-PGF₂α**, **PGDM** or **N-methyl-histamine**—on ≥2 occasions[12][27][28].

3. **Symptom improvement with mast-cell–directed therapy**, typically H₁/H₂ antihistamines, leukotriene antagonists or cromolyn[2][19].

Primary and secondary causes must be excluded, often requiring bone-marrow biopsy, KIT mutation testing and allergy evaluation[3][4].

Laboratory and Histological Hallmarks

* Basal serum tryptase > 20 ng/mL is a **minor criterion** for SM but not diagnostic of MCAS alone[17][29].

* Dense multifocal clusters (≥ 15 cells) of **CD117⁺ mast cells** with spindle morphology confirm SM[17].

* Flow cytometry showing aberrant **CD25/CD2/CD30 expression** supports clonality[17].

* Sensitive droplet-digital PCR detects **KIT D816V** down to 0.003% allele burden, aiding early diagnosis[30][31].

Differential Diagnosis

Flushing with gastrointestinal symptoms also occurs in **carcinoid syndrome, pheochromocytoma, medullary thyroid carcinoma, scromboid poisoning and menopause**, necessitating targeted biochemical and imaging studies[32][33]. Overlapping autonomic complaints require distinction from **postural tachycardia syndrome, Ehlers–Danlos hypermobility and chronic infection**, all of which frequently coexist with MCAS[22][23].

Comorbidities and Overlapping Syndromes

Large series reveal high rates of **anxiety, depression, dysautonomia, hypermobile Ehlers–Danlos syndrome and functional gastrointestinal disorders** among MCAS patients[21][22][34]. These associations may stem from shared connective-tissue or immune dysregulation and should be addressed concurrently to optimise quality of life[22][23].

Management Strategies

| Step | Intervention | Evidence base |

|---|---|---|

| **1 – Trigger avoidance & education** | Identify foods, drugs, physical stimuli; provide adrenaline auto-injector | Expert consensus[19][23] |

| **2 – Symptom control** | Up-dosed **H₁** and **H₂ antihistamines**, leukotriene receptor antagonists, cromolyn, ketogenic or low-histamine diet | Primary-care guide[35] |

| **3 – Escalation** | **Omalizumab** for refractory mediator symptoms; **ketotifen**, prostaglandin inhibitors; low-dose naltrexone | Yardstick recommendations[5] |

| **4 – Clonal disease-specific** | **Midostaurin** or **avapritinib** for advanced SM; cytoreductive chemotherapy; allogeneic transplant rarely | WHO/ICC guidelines[4][17] |

Early data suggest **nintedanib** and structural analogues selectively inhibit KIT D816V and may broaden options for aggressive disease[18].

Emerging Research and Future Directions

• Validation of individualised tryptase reference ranges considering genetic copy number variations aims to refine MCAS diagnostics[29][25].
• Ongoing trials of next-generation **KIT inhibitors** and **DP₂ antagonists** target mediator release more specifically[18][15].
• Multi-omics studies are exploring why only a minority of patients with KIT mutations develop organ damage, hoping to identify prognostic biomarkers[36].

Conclusion

MCAD represents a heterogeneous group of disorders unified by **recurrent, systemic mast-cell mediator release**. Accurate diagnosis rests on recognising characteristic symptom patterns, documenting biochemical activation with the **20% + 2 rule** or urinary metabolites, and excluding clonal or allergic mimics. Advances in molecular diagnostics, consensus classification and targeted therapy now enable more precise phenotyping and personalised management. A structured symptom checklist—anchored in the systems outlined above—remains the clinician’s most practical tool for early recognition, appropriate testing and timely intervention in these often-debilitating disorders.

Sources

[1] Mast cell activation syndrome - Wikipedia https://en.wikipedia.org/wiki/Mast_cell_activation_syndrome

[2] Mast Cell Activation Syndrome: Proposed Diagnostic Criteria https://pmc.ncbi.nlm.nih.gov/articles/PMC3753019/

[3] Using the Right Criteria for MCAS - PMC https://pmc.ncbi.nlm.nih.gov/articles/PMC10866766/

[4] The 2023 Updated Classification and Diagnostic Criteria of ... https://juniperpublishers.com/ctoij/pdf/CTOIJ.MS.ID.556141.pdf

[5] Management of indolent mastocytosis and mast cell activation ... https://pubmed.ncbi.nlm.nih.gov/40592381/

[6] Mastocytosis - Symptoms, Causes, Treatment | NORD https://rarediseases.org/rare-diseases/mastocytosis/

[7] Idiopathic mast cell activation syndrome is more often suspected ... https://onlinelibrary.wiley.com/doi/10.1111/all.15304

[8] Low Prevalence of Idiopathic Mast Cell Activation Syndrome Among ... https://www.sciencedirect.com/science/article/abs/pii/S2213219823013107

[9] True prevalence of idiopathic MCAS is lower than expected https://www.aaaai.org/tools-for-the-public/latest-research-summaries/the-journal-of-allergy-and-clinical-immunology-in/2023/mcas

[10] Mastocytosis - Wikipedia https://en.wikipedia.org/wiki/Mastocytosis

[11] Mast cell activation syndrome: An up-to-date review of literature - PMC https://pmc.ncbi.nlm.nih.gov/articles/PMC11212760/

[12] Prostaglandin D2 (PGD2) - Sheffield Laboratory Medicine https://sheffieldlaboratorymedicine.nhs.uk/search-test.php?search=3024

[13] Final Diagnosis -- Mast cell activation syndrome (secondary) https://path.upmc.edu/cases/case867/dx.html

[14] Role of prostaglandin D2 in mast cell activation-induced ... https://pmc.ncbi.nlm.nih.gov/articles/PMC3652067/

[15] PGD2 deficiency exacerbates food antigen-induced mast cell ... https://www.nature.com/articles/ncomms8514

[16] Diagnosis and Investigation of Mast Cell Activation Disorders and ... https://www.allergy.org.au/hp/papers/testing-for-mast-cell-activation-disorders-and-syndrome

[17] Review and Updates on Systemic Mastocytosis and Related Entities https://pmc.ncbi.nlm.nih.gov/articles/PMC10705510/

[18] Nintedanib targets KIT D816V neoplastic cells derived from induced ... https://ashpublications.org/blood/article/137/15/2070/474778/Nintedanib-targets-KIT-D816V-neoplastic-cells

[19] Mast cell activation syndrome - Symptoms, diagnosis and treatment https://bestpractice.bmj.com/topics/en-gb/3000310

[20] Systemic mastocytosis - Symptoms and causes - Mayo Clinic https://www.mayoclinic.org/diseases-conditions/systemic-mastocytosis/symptoms-causes/syc-20352859

[21] Characterization of Mast Cell Activation Syndrome - PMC https://pmc.ncbi.nlm.nih.gov/articles/PMC5341697/

[22] Neuropsychiatric Manifestations of Mast Cell Activation Syndrome ... https://pmc.ncbi.nlm.nih.gov/articles/PMC10672129/

[23] Mast Cell Activation Syndrome - PoTS UK https://www.potsuk.org/about-pots/associated-conditions/mcas/

[24] Why the 20% + 2 Tryptase Formula Is a Diagnostic Gold ... - PubMed https://pubmed.ncbi.nlm.nih.gov/31256161/

[25] Defining baseline variability of serum tryptase levels improves ... https://ncifrederick.cancer.gov/ScientificLibrary/Publication/Approved.aspx?Id=18501

[26] Why the 20% + 2 Tryptase Formula Is a Diagnostic Gold Standard ... https://pmc.ncbi.nlm.nih.gov/articles/PMC7115850/

[27] Biomarkers in the diagnosis of mast cell activation - PMC https://pmc.ncbi.nlm.nih.gov/articles/PMC11676608/

[28] MCAS, urine PG D2, 2,3-dinor-11beta-prostaglandin F2 alpha https://www.aaaai.org/allergist-resources/ask-the-expert/answers/old-ask-the-experts/macs-urine

[29] The Normal Range of Baseline Tryptase Should Be 1 to 15 ng/mL ... https://pmc.ncbi.nlm.nih.gov/articles/PMC11869997/

[30] Improved Detection of the KIT D816V Mutation in Patients with ... https://pmc.ncbi.nlm.nih.gov/articles/PMC3279709/

[31] KIT (D816V) Mutation by ddPCR, Quantitative - ARUP Laboratories https://ltd.aruplab.com/Tests/Pub/3002956

[32] Flushing Disorders Associated with Gastrointestinal Symptoms: Part ... https://pmc.ncbi.nlm.nih.gov/articles/PMC6108509/

[33] Mastocytosis Presenting as a Recurrence of Syncopal Episodes https://www.journalmc.org/index.php/JMC/article/view/254/200

[34] Prevalence and Treatment Response of Neuropsychiatric Disorders ... https://www.sciencedirect.com/science/article/pii/S2666354625001061

[35] [PDF] Mast Cell Activation Syndrome (MCAS ) A Primary Care Guide https://www.mastcellaction.org/assets/_/2025/04/01/d6de24e1-f6f6-4248-a3f4-12866d7bf713/mast-cell-activation-syndrome-mcas-a-primary-care-guide-final.pdf?v=1

[36] Systemic mastocytosis in adults: 2023 update on diagnosis, risk ... https://onlinelibrary.wiley.com/doi/10.1002/ajh.26962

[37] Systemic Mastocytosis Symptoms, Diagnosis, Treatment ... https://www.aaaai.org/conditions-treatments/related-conditions/systemic-mastocytosis

[38] Defining baseline variability of serum tryptase levels improves ... https://pmc.ncbi.nlm.nih.gov/articles/PMC9126046/

[39] Mast Cell Activation Syndrome (MCAS) https://www.aaaai.org/conditions-treatments/related-conditions/mcas

[40] Diagnosis of mast cell activation syndrome in the UK explained https://syncope.co.uk/mast-cell-activation-syndrome/diagnosis-of-mast-cell-activation-syndrome/

[41] [EPUB] Defining “Normal” basal serum tryptase levels - Frontiers https://www.frontiersin.org/journals/allergy/articles/10.3389/falgy.2025.1592001/epub

[42] Mast Cell Activation Syndrome: Symptoms, Causes, and Treatment https://www.webmd.com/allergies/what-is-mast-cell-activation-syndrome

[43] Mastocytosis: Types, Symptoms & Treatment - Cleveland Clinic https://my.clevelandclinic.org/health/diseases/5908-mastocytosis

[44] Diagnosing MCAS - Mast Cell Action https://www.mastcellaction.org/diagnosing-mcas

[45] KIT D816V - My Cancer Genome https://www.mycancergenome.org/content/alteration/kit-d816v/

[46] Genetically defined individual reference ranges for tryptase limit ... https://ashpublications.org/bloodadvances/article/7/9/1796/486713/Genetically-defined-individual-reference-ranges

[47] Systemic mastocytosis with flushing and hypotension: A case report ... https://pmc.ncbi.nlm.nih.gov/articles/PMC7938450/

[48] Mastocytosis and Mast Cell Activation Disorders: Clearing the Air https://www.mdpi.com/1422-0067/22/20/11270

[49] The Recurrent Flush: A Case and Review of Systemic Mastocytosis https://utppublishing.com/doi/10.22374/cjgim.v13i2.234

[50] Mastocytosis - NHS https://www.nhs.uk/conditions/mastocytosis/

[51] Epidemiology of mastocytosis: a population-based study (Sweden) https://medicaljournalssweden.se/actaoncologica/article/view/31406/45434

[52] Mast cell activation symptoms are prevalent in Long-COVID https://www.sciencedirect.com/science/article/pii/S1201971221007517

[53] [PDF] Mast Cell Activation Syndrome – What it Is and Isn't https://med.virginia.edu/ginutrition/wp-content/uploads/sites/199/2020/06/Mast-Cell-Activation-Syndrome-June-2020.pdf

[54] Impact of mental health on disease activity in mastocytosis during ... https://www.sciencedirect.com/science/article/pii/S1323893021000903

[55] Indolent Systemic Mastocytosis: An Incidental Diagnosis https://www.acpjournals.org/doi/10.7326/aimcc.2024.0118

[56] Prostaglandin DM (PGDM) - Sheffield Laboratory Medicine https://sheffieldlaboratorymedicine.nhs.uk/search-test.php?search=3100

[57] Understanding serum tryptase variability and anaphylaxis https://www.aaaai.org/tools-for-the-public/latest-research-summaries/the-journal-of-allergy-and-clinical-immunology/2021/tryptase

[58] The 2023 Updated Classification and Diagnostic Criteria of ... https://juniperpublishers.com/ctoij/CTOIJ.MS.ID.556141.php

[59] [PDF] Urinary 9a,11b-Prostaglandin F2 in Children with Atopic Eczema https://www.medicaljournals.se/acta/download/10.1080/00015550410035515/

[60] Prostaglandin F2 Alpha (PGDF) - Sheffield Laboratory Medicine https://sheffieldlaboratorymedicine.nhs.uk/search-test.php?search=3032

[61] Selecting the Right Criteria and Proper Classification to Diagnose ... https://www.sciencedirect.com/science/article/pii/S2213219821006760